Sentence examples for 1 tablets from inspiring English sources

Residual chlorine content was tested using the Lovibond Comparator using DPD 1 tablets (N,N Diethyl-1.4 Phenylenediamine sulphate) to check colour changes.

Children were treated with SP (Fansidar®, Roche, France) by weight (1 tablet containing 500 mg sulfadoxine and 25 mg pyrimethamine; ½ tablet for weights 4.5 10 kg, 1 tablet for 11 20 kg, 1½ tablets for 21 30 kg).

The dosage of SP (tablets of 500 mg sulfadoxine and 25 mg pyrimethamine) was ½ tablet (<12 kg) or 1 tablet (> = 12 kg), dosage of AS (50 mg tablets) was 1 tablet per dose (<12 kg) or 1.25 tablets (> = 12 kg), and dosage of AQ (200 mg tablets), ¾ tablet for children <12 kg and 1.25 tablets for children > = 12 kg.

Dosing by body weight was 1 tablet if < 15 kg, 2 tablets if 15 24 kg, 3 tablets if 25 34 kg, and 4 tablets if ≥ 35 kg.

The AS+AQ was Arsucam coblister (AS 50 mg/AQ 153 mg; Sanofi-Aventis, Paris, France), given once daily for 3 days to the following scheme: for patients < 10 kg, 1/2 tablet AS + 1/2 tablet AQ; 10 20 kg, 1 tablet AS+ 1 tablet AQ; 21 40 kg, 2 tablets AS+ 2 tablets AQ; > 40 kg, 4 tablets AS+ 4 tablets AQ.

Tablets were administered according to the manufacturer's instructions: 5 to 14.9 kg, 1 tablet; 15 to 24.9 kg, 2 tablets; 25 to 34.9 kg, 3 tablets; and >35 kg, 4 tablets.

The AL was Coartem (Novartis Pharma AG, Basel, Switzerland), given twice daily for 3 days to the following scheme: for patients < 15 kg, 1 tablet; 15 24 kg, 2 tablets; 25 34 kg, 3 tablets; ≥ 35 kg, 4 tablets.

In all studies, AL dosing was based on body weight: 5 < 15 kg, 1 tablet per dose; 15 < 25 kg, 2 tablets per dose; 25 < 35 kg, 3 tablets per dose; ≥ 35 kg, 4 tablets per dose.

DP (Dartepp; Guilin Pharmaceutical China; 40 mg dihydroartemisinin and 320 mg piperaquine, each tablet) was administered once a day for 3 days according to body weight with the following scheme: 5 to 7.9 kg, 0.5 tablet; 8 to 9.9 kg, 0.75 tablet; 10 to 14.9 kg, 1 tablet; 15 to 20.9 kg, 1.5 tablets; and 21 to 29.9 kg, 2.0 tablets.

Currently, aliskiren can be claimed 150 mg (1 tablet) daily.

Most patients were instructed to take 1 tablet 1×/day for 20 days; others were instructed to take 1 tablet 2×/day for 5 or 10 days.